Research News

ALS United and its dedicated member organizations have made a significant step in the fight against Amyotrophic Lateral Sclerosis (ALS) by supporting the Accelerating Medicines Partnership (AMP) ALS initiative. This groundbreaking project, managed by the Foundation for the National Institutes of Health (FNIH), aims to expedite the development of effective treatments for ALS. It brings together the resources and expertise of the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH), the Food and Drug Administration, Critical Path Institute, and other stakeholders from academia, life science companies, foundations, and patient-focused groups.

ALS United member organizations have pledged $100,000 annually over five years to support AMP ALS. This commitment enables ALS United to actively participate in the steering committee, ensuring that the voices of people living with ALS are central to the initiative and fostering a collaborative approach to advancing research and therapeutic development.

The AMP ALS initiative addresses critical challenges in ALS research. By establishing a central ALS Knowledge Platform and validating biomarkers, AMP ALS aims to improve clinical outcome assessments and discover new therapeutic targets. ALS United’s vision, “Together, We End ALS,” highlights the importance of collaboration in tackling this devastating disease, funding innovative local care services, and supporting those living with ALS.